DBV Technologies S.A. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DBV Technologies S.A. on June 18, 2024. The filing addresses a notice regarding the listing status of the Company's American Depositary Shares (ADSs) on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Tier Transfer: Nasdaq granted the Company's request to transfer its ADSs from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, effective June 20, 2024.
- Compliance Extension: Nasdaq granted a second 180-calendar day compliance period to regain compliance with the minimum bid price requirement, extending the deadline to December 16, 2024.
- Trading Symbol: The ADSs will continue to trade on Nasdaq under the symbol "DBVT" without expected disruption.
Outlook, Risks, and Contingencies
The Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance with Rule 5550(a)(2). If the Company fails to cure the bid price deficiency by December 16, 2024, Nasdaq will provide written notice of delisting. The Company may request a hearing before the Nasdaq Hearings Panel to stay delisting actions. Management stated there can be no assurance that the Company will be able to regain compliance with the rule or other listing criteria.
Investor Verification Checklist
- Verify the current closing bid price of DBVT ADSs to assess progress toward the $1.00 threshold.
- Monitor the Company's ability to maintain a closing bid price of at least $1.00 for 10 consecutive business days before December 16, 2024.
- Review the implications of trading on The Nasdaq Capital Market tier versus The Nasdaq Global Select Market tier.
- Check for any future announcements regarding a hearing request if the bid price deficiency is not cured by the deadline.